Accord Healthcare
is a young and dynamic pharmaceutical company, involved in the development, manufacturing and distribution of pharmaceutical products to over 50 markets around the world
Accord este una dintre companiile cu cea mai rapida crestere din sectorul european de medicamente generice. Compania utilizeaza solutii dedicate pentru a asigura calitatea produselor sale oncologice in conformitate cu standardele exigente ale UE. Conformitatea cu procedurile extrem de stricte este monitorizata de echipe de control al calitatii desemnate special in acest scop.
Accord este una dintre companiile cu cea mai rapida crestere din sectorul european de medicamente generice. Compania utilizeaza solutii dedicate pentru a asigura calitatea produselor sale oncologice in conformitate cu standardele exigente ale UE. Conformitatea cu procedurile extrem de stricte este monitorizata de echipe de control al calitatii desemnate special in acest scop.
ACCORD UK
ACCORD EUROPE
ACCORD WORLDWIDE
ACCORD IN POLAND
ACCORD UK
Accord UK was set up and commercialised its first product in 2008.
Accord now has a consolidated presence in both hospital and retail sectors and is one of the fastest growing generic pharmaceutical companies in the UK.
ACCORD EUROPE
Accord is one of the fastest growing generic companies in the world. In the most recent financial year Accord Europe posted revenue growth of over 100%.
Accord has one of the most extensive sales, marketing and distribution network in Europe. Headquartered from UK, Accord now supplies products in over 30 European countries. Sales growth in the last 12 months was over 100% bringing revenues close to $100 million and significant double digit growth is anticipated in the coming year. Accord has a particular strength in the hospital or institutional setting and last year sales associated with this segment grew 197%.
Accord Europe currently has over 4000 product approvals across 107 INNs and this number is expected to grow significantly over the next few years allowing Accord to compete with some of the biggest portfolios in the industry.
Accord has also invested significantly in an increasing commercial infrastructure across the region and manages its own warehousing, logistics, regulatory, quality, intellectual property and sales and marketing requirements within region. A key value add for Accord Europe is its own warehousing and packaging complex located near Cambridge UK, which facilitates high degree of supply chain flexibility. Accord’s dedicated market sales-forces reach over 75% of the patient population of the EU.
Expansion of trading presence in existing markets: UK, Spain, Italy, France, Netherlands, Sweden, Denmark and Austria. All existing EU markets posted sales growth.
Established commercial activities in: Germany, Norway, Belgium, Luxemburg, Finland, Ireland, Estonia, Portugal, Slovakia, Slovenia, Hungary, Iceland, Latvia, Bulgaria, Romania, Belarus, Malta, Albania, Cyprus, Czech Republic and Poland.
Took part in over 1800 tender processes.
Launched over 1000 products in up to 28 European markets.
Created a dedicated business development function comprising 5 experienced staff. In 2012 dossiers for over 20 INNs were acquired or in-licenced.
20 regulatory procedures submitted and 90 new molecules (INN) entered development
For more information, visit (http://www.accord-healthcare.eu).
ACCORD WORLDWIDE
With an extensive presence in North America, Europe, South America, Australia, New Zealand and South Africa and more recently in the MENA region, Accord Healthcare has very rapidly become one of the fastest growing generic pharmaceutical companies. With a robust product portfolio in growth oriented therapies, such as Oncology, Cardiology, Neurology, Nephrology, Urology, Psychiatry, Diabetology, Pain management and Gastroenterology and over 4000 product approvals (as of June, 2013) in various markets, Accord’s sales, marketing and distribution network now reaches over 60 countries.
Accord has grown both in organic & inorganic way towards expanding its product portfolio and operations in various parts of the world. Our North America and European operations were started with a strategic vision to create a global brand in the world’s largest pharmaceutical markets, supported by a commercial infrastructure that enables us to bring our high quality yet affordable products to patients. The same philosophy is extended to other regions of the world.
Today, Accord is marketing over 130 products all over the world and this number is going to increase significantly over the next few years considering our strong pipeline of products awaiting marketing approval from health & regulatory authorities and products in the development pipeline. Our large and growing portfolio allows us to compete with some of the biggest portfolios in the industry as well as helps to extend our presence into new markets.
Accord is committed to uncompromised quality for its products and services across the globe. Our products are manufactured under the highest international standards and our manufacturing plants are approved by major global regulatory agencies such as the USFDA, MHRA, EMA, TGA, MCC, ANVISA and other. Our product quality demonstrates a broader commitment to healthcare that is supported by a wide variety of products, across most therapeutic areas and helps improve the well being of patients around the world.
We commit ourselves to challenging the unmet medical, societal and patient needs of the day.
ACCORD W POLSCE
Accord Poland was set up in 2010 in Warsaw and has a consolidated presence in both hospital and retail sectors.
The Accord Poland office is situated in Warsaw, capital of Poland in Marynarska Business Park, which was recognised at the CEE Real Estate Quality Awards as “The Best Office Development of 2008 in the CEE.”